What do systematic reviews say?

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.07 [0.86, 1.33]
  2 studies · 1869 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.02 [0.79, 1.32]
  4 studies · 3266 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1 [0.31, 3.28]
  4 studies · 3266 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2708 participants
  High

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.07 [0.87, 1.32]
  2 studies · 1520 participants
  Moderate

Indacaterol vs long‐acting beta2‐agonist alone

Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).

• Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes only
  OR 1.11 [0.94, 1.32]
  3 studies · 2536 participants
  Moderate